Time to challenge treatment options in 1L mCRPC; LYNPARZA in PROpel

Training Course • AstraZeneca

About the CPD course

The presentation aims to highlight the evolving landscape of 1L mCRPC therapy; as well as licensing and reimbursement of LYNPARZA (olaparib) in mCRPC. The presentation will explore key efficacy and safety outcomes of LYNPARZA combination therapy vs. abiraterone plus prednisone/prednisolone in the PROpel trial. It will also identify clinical practice patients with mCRPC who could be eligible candidates for LYNPARZA and raise the standard of care for them.

CPD Provider

AstraZeneca

View Profile

Send an enquiry

Full Name*

Email Address*

Contact Number*

Industry*

Your Enquiry*

By submitting this form, you consent to CPD sending you email regarding your application.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AstraZeneca

At AstraZeneca, we are transforming the future of healthcare by unlocking the power of what science can do – for people, society and the planet. The UK plays a key role within the global AstraZeneca network. It is home to colleagues from across the full life sciences value chain. Everything we do is driven by science to transform healthcare and patient outcomes, while playing a purpose-led role in wider society.